Background. Survival benefit from adjuvant chemotherapy is established for stage III colon cancer; however, uncertainty exists for stage II patients. Tumor heterogeneity, specifically microsatellite instability (MSI), which is more common in right-sided cancers, may be the reason for this observation. We examined the relationship between adjuvant chemotherapy and overall 5-year mortality for stage II colon cancer by location (right-vs left-side) as a surrogate for MSI. Methods. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we identified Medicare beneficiaries from 1992 to 2005 with AJCC stage II (n = 23,578) and III (n = 17,148) primary adenocarcinoma of the colon who underwent surgery for curative intent. Overall 5-year mortality was examined with Kaplan-Meier survival analysis and Cox proportional hazards regression with propensity score weighting.
still receiving this treatment. 2 Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database, Schrag et al. 3 found that between 1991 and 1996, 27 % of patients older than age 65, with surgically resected stage II colon cancer received chemotherapy. This pattern was recently confirmed by O'Connor et al. 4 using an updated SEER-Medicare database from 1992 to 2005.
With recent attention on tumor biology and the recognition that there is a great deal of heterogeneity, should we be asking whether there is a subset of patients with stage II colon cancer who would be more likely to benefit from adjuvant chemotherapy? [5] [6] [7] [8] [9] [10] Heterogeneity in microsatellite instability (MSI) status is common in colon cancers and is an independent predictor of survival: MSI-high tumors have a better overall prognosis and significantly decreased risk of metastases. [11] [12] [13] [14] [15] Ribic et al. investigated the effectiveness of adjuvant chemotherapy with fluorouracil for both stage II and stage III colon cancer patients by MSI status. 11 They found a survival benefit from fluorouracilbased adjuvant chemotherapy for microsatellite-stable and MSI-low stage II and stage III colon cancers, but not for those with MSI-high tumors.
MSI is seen predominantly in right-sided colon cancers with an estimated 20-25 % of right-sided stage II cancers being MSI-high; MSI-high tumors of the left colon rarely exist, across all stages. 10, 12, [16] [17] [18] [19] This raises the possibility for a differential benefit from chemotherapy based on tumor location. We used the linked SEER-Medicare dataset to examine the relationship between adjuvant chemotherapy and overall 5-year mortality for right-versus left-sided stage II colon cancer. We hypothesized that left-sided stage II cancers would demonstrate a greater benefit from receipt of adjuvant chemotherapy compared with right-sided cancers.
METHODS
This study was reviewed by the University of Wisconsin-Madison Health Sciences Institutional Review Board and determined to be exempt.
Data Sources
We used the linked SEER registry and Medicare claims databases to identify patients diagnosed with colon cancer between 1992 and 2005. SEER cancer registry information includes patient demographics, tumor characteristics, first course of treatment, and survival for persons newly diagnosed with cancer. The SEER-Medicare dataset has successfully linked 93 % of individuals aged 65 or older at diagnosis to their Medicare record. 20, 21 Patient Selection All Medicare-enrolled patients aged 66 years and older diagnosed in a SEER area from 1992 to 2005 were eligible for our study if they had a diagnosis of colon (International Classification of Diseases for Oncology ICD-O-3 site codes 18.0-18.9, and 19.9) adenocarcinoma (ICD-O-3 morphology codes 8140-47,  8210-11, 8220-21, 8260-63, 8480 -81, and 8490) that were diagnosed at either American Joint Committee on Cancer (AJCC) stage II or III. Patients with rectal cancer (site code 20.9) were excluded, as well as patients with mucinous cystadenocarcinoma (morphology code 8470). 22 We further selected for patients who underwent surgery for likely curative intent within 6 months of diagnosis by using International Classification of Diseases, ninth revision, Clinical Modification (ICD-9-CM) procedure codes: 45.79 (partial excision of large intestine) and 45.89 (total intraabdominal colectomy). Patients were also required to have continuous enrollment in Medicare Part A and B from 12 months prior to the date of their diagnosis to 5 years following date of discharge, death, or December 31, 2005 to facilitate ascertainment of overall health status, postoperative chemotherapy administration, and survival. Patients were excluded who were also enrolled in a Health Maintenance Organization during the same time period, diagnosed with another malignancy 1 year before or after the date of colon cancer diagnosis, or if their first diagnosis of colon cancer was made after death (i.e., on autopsy).
From an initial cohort of 46,627 patients, sequential exclusions were carried out for tumors with an unknown location or from the appendix (site codes 18.8, 18.9, and 18.1), unknown tumor grade, initial cancer treatment other than surgery (preoperative radiation or chemotherapy), missing nodal assessment, and death within 30 days of surgery or prior to discharge from the surgical hospitalization, yielding a final sample size was 40,726 patients.
Outcome Variable The primary outcome measure was all-cause 5-year mortality, defined as death within 5 years of primary surgery for colon cancer from the SEER Patient Entitlement and Diagnosis Summary File (PEDSF).
Explanatory Variables
The primary explanatory variable was receipt of adjuvant chemotherapy. We defined postoperative chemotherapy based on prior work by Bradley et al.23, Dobie et al. 24 , and our recently published paper on adjuvant chemotherapy for stage II colon cancer patients with poor prognostic features. 4 Claims were included within the following treatment window: beginning with the date of primary surgery and ending with (a) claim date after which there were 3 months free of colon cancer treatment, (b) evidence of distant cancer recurrence, or (c) 9 months after primary surgery, whichever came first. 23, 24 Patients with at least 1 claim in this treatment window were classified as having received any chemotherapy, without differentiation between type of chemotherapy received. Capecitabine administration was captured using Healthcare Common Procedure Coding System (HCPCS) codes J8520 and J8521. Patients without any claims in this treatment window were considered to have received no chemotherapy.
Analyses were stratified by tumor location and AJCC stage. Dividing tumor location into right and left side follows a validated approach described by Meguid et Census tract median level of household income and median level of education were used as proxies for patient socioeconomic status. Patient risk adjustment and treatment variables included hospitalization in the year prior to diagnosis, the presence of any in-hospital complication, and a score for overall health status. 28 Each patient was assigned a Centers for Medicare and Medicaid Services Hierarchical Condition Categories (HCC) score. 29 HCC score is a measure of healthcare utilization and was used as a marker of overall health status. Data on oncologist visit within 30 days of surgical discharge was also extracted. We also incorporated several cancer-specific variables, including year of diagnosis (divided into periods of colonoscopy coverage by Medicare) and poor prognostic features (diagnosis in the setting of intestinal obstruction or perforation, emergent admission for surgery, T4 stage, poor/undifferentiated tumor histology, and fewer than 12 lymph nodes examined at surgery).
2,30
Statistical Analyses We compared the frequency of all patient sociodemographics, risk adjustment, treatment, and cancer-specific variables by receipt of chemotherapy (none vs any) for right-and left-sided colon cancers within each stage (II-III) using v 2 tests for categorical variables and 2-way analysis of variance tests for continuous variables. Cox proportional hazards regression was conducted to obtain adjusted hazards ratios (HRs) and 95 % confidence intervals (95 % CIs) for all-cause 5-year mortality for patients who did or did not receive chemotherapy by tumor location within each stage group, controlling for all other variables.
In clinical practice, decisions to treat patients with chemotherapy are based on a number of factors including age, comorbidities, tumor stage and grade, lymphovascular invasion, and patient/provider preferences. We further adjusted the Cox proportional hazard ratios with propensity score weighting to address potential bias in estimates of the true treatment effect given the observational nature of the dataset. [31] [32] [33] [34] Propensity scores were calculated for each patient using models to estimate each patient's probability of receiving adjuvant chemotherapy conditional on sociodemographic and clinical characteristics (Table 1) . Propensity score weights based on the inverse of the propensity score were included in the fully adjusted models. 35 Kaplan-Meier survival analysis was adjusted for propensity scores. Overall 5-year survival rates were compared for patients receiving any versus no adjuvant chemotherapy within each stage (II-III) and stratified by location (rightvs left-sided colon cancer).
Analyses were conducted with Stata 12.0 software (StataCorp, College Station, TX, USA). All tests of significance used 2-sided p values at the p \ .05 level; 95 % CIs were calculated using robust estimates of the standard error. 
RESULTS

Sample Characteristics
We included 40,726 patients in our study using the patient selection algorithm described in the Methods section and stratified groups by AJCC stage and tumor location. It was found that 18 % (n = 2941) of stage II patients with right-sided cancer and 22 % (n = 1693) with left-sided cancer received adjuvant chemotherapy compared with 56 % (n = 6496) of stage III right-sided cancer and 60 % (n = 3284) with stage III left-sided cancer.
Patients who received adjuvant chemotherapy were more likely to be younger, white, male, and married; have a higher household income; be diagnosed with a more advanced tumor; have a better HCC score; have fewer hospitalizations in the previous year; and be seen by an oncologist within 30 days of surgery. Similar patterns were seen within tumor location groups for stage II (Table 2) and stage III patients (Table 3) . (Table 4 ). However, after adjustment for all patient sociodemographic, risk adjustment, treatment, and cancer-specific variables, patients with stage II (Fig. 1a-d 
DISCUSSION
Adjuvant chemotherapy is standard of care for patients with resected stage III colon cancer, while the benefit for stage II patients remains unclear.
1 Some studies have found no significant survival benefit for stage II patients who receive this treatment, while others report a definite benefit of adjuvant chemotherapy over surgery alone for stage II patients. 3, 4, 36, 37 However, the majority of evidence shows only a small absolute survival benefit, in the range of 2-4 %. [38] [39] [40] This small benefit needs to be compared with the high likelihood of side effects from treatment. Given the previously identified relationship between MSI and response to chemotherapy, our primary aim was to determine if a AJCC American Joint Committee on Cancer, SD standard deviation, HCC hierarchical condition categories subset of patients with stage II colon cancer, defined by tumor location as a surrogate for MSI status, could be identified that received a survival benefit from adjuvant chemotherapy. We found that, after controlling for multiple patient, risk adjustment, treatment, and cancer-specific variables in addition to propensity score weighting, there was no survival benefit for either stage II right-sided or stage II left-sided colon cancer patients who received any adjuvant chemotherapy compared with those who did not. Consistent with previous studies, we do show a significant survival benefit for stage III patients who receive adjuvant chemotherapy, regardless of tumor location. 4, 37, 39, [41] [42] [43] [44] [45] [46] Colon tumor heterogeneity has been described by many groups. [5] [6] [7] More specifically, different gene expressions have been described between tumors in the right and left colon, such as higher MSI in right-sided cancers and more chromosomal instability in left-sided cancers. [8] [9] [10] In a previous study, Ribic et al. 11 found a differential benefit from fluorouracil-based adjuvant chemotherapy for both stage II and stage III colon cancers with microsatellitestable and MSI-low tumors compared with those with MSIhigh tumors. Also, further analysis of patients included in the MOSAIC trial points to a potential benefit of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin in patients with MSI-high stage III colon cancer. 37, 47 MSI-high tumors are more prevalent on the right side of the colon and even more so in stage II right-sided cancers. 10, [16] [17] [18] [19] 48 MSI status of a tumor is not always readily available. In this study, we used tumor location (right-vs left-side) as a proxy for MSI status and did not find any significant benefit for traditional fluorouracil-based adjuvant chemotherapy for either stage II right-sided or stage II left-sided colon cancers.
There are limitations to this study. First, we examine only Medicare beneficiaries age 66 years and older at the time of diagnosis, which limits the applicability. Molecular etiologies of MSI in colon cancers are associated with age. MSIhigh tumors in patients less than 50 years old are four times more likely to be due to a germline mutation in a DNA mismatch repair gene than in patients older than 50, who are four times more likely to have MSI due to MLH1 methylation. 16 This study should be repeated in a broader population before applying our results to younger patients. Second, unmeasured factors such as patient preferences or provider practice patterns may play a role in patient outcome. We attempted to limit the impact of these unmeasured factors by adjusting our models with propensity score weighting for receipt of chemotherapy and including a clinically relevant patient, risk-adjustment, and treatment variables in our final models. The major limitation of this study is the fact that MSI status was not available in this data set, which prohibits direct testing of our hypothesis that MSI status impacts benefit from adjuvant chemotherapy in this population of patients. A related limitation is that due to the administrative claim data from Medicare, we were unable to specifically look at survival benefit by type of adjuvant chemotherapy. This limitation is especially relevant in light of the recent findings from further analysis of patients in the MOSAIC trial. 37, 47 Further studies are needed to examine the effect of different types of adjuvant chemotherapy by colon cancer location and MSI status.
Despite these limitations, our findings add to the existing literature surrounding the controversy of adjuvant chemotherapy in stage II colon cancers. We know that substantial numbers of patients with stage II colon cancer continue to receive adjuvant chemotherapy despite current guidelines that do not recommend routine use. 2 Our results reinforce these guidelines and show that a simple division of stage II colon cancers as right-or left-sided does not identify a subgroup of patients that might receive benefit from adjuvant chemotherapy. When added to the existing literature, our results highlight the fact that the relationship between tumor biology, tumor location, and response to adjuvant chemotherapy is not straightforward. Future efforts to personalize treatment of colon cancers will likely involve direct gene expression testing for each individual. This practice will also continue to play an important role in shaping future clinical trials that examine adjuvant chemotherapy regimens for colon cancer.
